Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration.

Parmeggiani F, Costagliola C, Gemmati D, D'Angelo S, Perri P, Campa C, Catozzi L, Federici F, Sebastiani A, Incorvaia C.

Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3100-6. doi: 10.1167/iovs.07-1654. Epub 2008 Mar 31.

PMID:
18378576
2.

Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.

Parmeggiani F, Costagliola C, Gemmati D, D'Angelo S, Perri P, Scapoli GL, Catozzi L, Federici F, Sebastiani A, Incorvaia C.

Pharmacogenet Genomics. 2007 Dec;17(12):1039-46.

PMID:
18004208
3.

Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.

Parmeggiani F, Gemmati D, Costagliola C, Semeraro F, D'Angelo S, Perri P, Sebastiani A, Incorvaia C.

Ophthalmology. 2010 Mar;117(3):517-23. doi: 10.1016/j.ophtha.2009.08.028. Epub 2009 Dec 30.

PMID:
20044141
4.

Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration.

Parmeggiani F, Costagliola C, Semeraro F, Romano MR, Rinaldi M, Gallenga CE, Serino ML, Incorvaia C, D'Angelo S, De Nadai K, Dell'Omo R, Russo A, Gemmati D, Perri P.

Int J Mol Sci. 2015 Aug 20;16(8):19796-811. doi: 10.3390/ijms160819796.

5.

Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.

Parmeggiani F, Gemmati D, Costagliola C, Sebastiani A, Incorvaia C.

Recent Pat DNA Gene Seq. 2009;3(2):114-22. Review.

PMID:
19519581
6.

Genetic predictors of response to photodynamictherapy.

Parmeggiani F, Gemmati D, Costagliola C, Semeraro F, Perri P, D'Angelo S, Romano MR, De Nadai K, Sebastiani A, Incorvaia C.

Mol Diagn Ther. 2011 Aug 1;15(4):195-210. doi: 10.2165/11592270-000000000-00000. Review.

PMID:
21913742
7.

Pharmacogenetic aspects in therapeutic management of subfoveal choroidal neovascularisation: role of factor XIII-A 185 T-allele.

Parmeggiani F, Costagliola C, Incorvaia C, Sebastiani A, Gemmati D.

Curr Drug Targets. 2011 Feb;12(2):138-48. Review.

PMID:
20887247
8.

Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.

Parmeggiani F, Gemmati D, Costagliola C, Sebastiani A, Incorvaia C.

Pharmacogenomics. 2009 Jan;10(1):81-95. doi: 10.2217/14622416.10.1.81. Review.

PMID:
19102718
9.

12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.

Incorvaia C, Campa C, Parmeggiani F, Menzione M, D'Angelo S, Della Corte M, Rinaldi M, Romano M, Dell'omo R, Costagliola C.

Retina. 2008 Feb;28(2):289-97. doi: 10.1097/IAE.0b013e31813ffe90.

PMID:
18301052
13.
14.

[Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].

Chen YX, Ge J, Yan M, Jin CJ, Zhang MX, Dong FT, Lu F, Zhang CF, Zhao JL.

Zhonghua Yan Ke Za Zhi. 2007 Mar;43(3):198-205. Chinese.

PMID:
17605900
15.
16.
17.

[Photodynamic therapy in age-related macular degeneration--results of one year observation].

Wykrota H, Gierek-Łapińska A.

Klin Oczna. 2002;104(3-4):239-43. Polish.

PMID:
12608309
19.
20.

Supplemental Content

Support Center